BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7720109)

  • 1. [Quantitative study of P53 gene protein expression in the benign disease and cancer of breast].
    Qi FY; Zuo LF; Zhen YJ
    Zhonghua Bing Li Xue Za Zhi; 1994 Dec; 23(6):330-3. PubMed ID: 7720109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of adhesive molecule CD44v6 and p53 gene in breast cancer tissues and its relation with DNA ploidy].
    Zuo WS; Wei L; Wang XW; Wang YS; Yu ZY
    Ai Zheng; 2004 Nov; 23(11 Suppl):1418-22. PubMed ID: 15566648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 protein expression in benign and malignant breast lesions.
    Ioakim-Liossi A; Markopoulos C; Karakitsos P; Safioleas M; Gogas J; Vaiopoulos G
    Acta Cytol; 1998; 42(4):918-22. PubMed ID: 9684577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assay of DNA content and estrogen receptor status in human breast cancer].
    Chen GJ; Shao YF; Shan Y
    Zhonghua Zhong Liu Za Zhi; 1994 Nov; 16(6):461-4. PubMed ID: 7720507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index.
    Alexiev BA; Bassarova AV; Popovska SL; Popov AA; Christov CZ
    Gen Diagn Pathol; 1997 Jun; 142(5-6):271-9. PubMed ID: 9228249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
    Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
    Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma.
    Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA
    Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of p53 expression and DNA ploidy pattern in esophageal cancer].
    Naitoh H; Kawaguchi A; Shibata J; Umeda T; Kodama M; Hattori T
    Gan To Kagaku Ryoho; 1995 Jun; 22 Suppl 2():110-4. PubMed ID: 7611771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
    Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53.
    Guo LL; Gao P; Wu YG; Jian WC; Hao CY; Li H; Lin XY
    Arch Med Res; 2007 Nov; 38(8):846-52. PubMed ID: 17923265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Male and female breast cancer--differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis.
    André S; Pinto AE; Laranjeira C; Quaresma M; Soares J
    Pathobiology; 2007; 74(6):323-7. PubMed ID: 18087196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P53 expression in patients with malignant and benign breast diseases.
    Kalogeraki A; Panayiotides J; Tamiolakis D; Tzardi M; Chaniotis V; Chalkiadakis G; Melissas J; Stiftsis D; Kanavaros P; Delides GS
    Anticancer Res; 2000; 20(3A):1801-5. PubMed ID: 10928110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Quantitative analyses of DNA content and P53 gene product expression from epithelial lacrimal gland tumors].
    Zhao P; Sun X
    Zhonghua Yan Ke Za Zhi; 1996 Nov; 32(6):424-8. PubMed ID: 9590808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [DNA ploidy pattern and p53 overexpression in gastric cancer].
    Tomisaki S; Tatsuo O; Hisao O; Sakaguchi Y; Kusumoto T; Ohno S; Ichiyoshi Y; Maehara Y; Sugimachi K
    Gan To Kagaku Ryoho; 1995 Jun; 22 Suppl 2():115-7. PubMed ID: 7611772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
    Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
    Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA ploidy pattern and tumor suppressor gene p53 expression in gallbladder carcinoma.
    Roa I; Villaseca M; Araya JC; Roa J; de Aretxabala X; Fuentealba P; Melo A
    Cancer Epidemiol Biomarkers Prev; 1997 Jul; 6(7):547-50. PubMed ID: 9232344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast.
    Geradts J; Ingram CD
    Mod Pathol; 2000 Sep; 13(9):945-53. PubMed ID: 11007034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Flow cytometry-pathology combined study of breast cancer].
    Yu ZY; Yu JM; Wu TH; Zhuo PY; Wang SF; Li M; Zhang X; Lü BY; Liu YB
    Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):420-2. PubMed ID: 16188128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.